These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25993017)

  • 21. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
    Kamata Y; Minota S
    Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
    Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.
    Briot K; Ravaud P; Dargent-Molina P; Zylberman M; Liu-Leage S; Roux C
    Osteoporos Int; 2009 Apr; 20(4):625-30. PubMed ID: 18661089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
    Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
    Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
    Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
    BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on "Variability of denosumab densitometric response in postmenopausal osteoporosis".
    Torrente-Segarra V; Roig-Vilaseca D
    Rheumatol Int; 2018 Jun; 38(6):1161-1162. PubMed ID: 29546636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS).
    Sato M; Tsujimoto M; Kajimoto K; Uetake H; Shimoda H; Fujiwara S
    Arch Osteoporos; 2018 Jul; 13(1):74. PubMed ID: 29978364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide.
    Nogues X; Luz Rentero M; Rodríguez AL
    Curr Med Res Opin; 2014 Feb; 30(2):287-96. PubMed ID: 24102317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using Osteoporosis Therapies in Combination.
    McClung MR
    Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic.
    Fuksa L; Vytrisalova M
    Curr Med Res Opin; 2015; 31(9):1645-53. PubMed ID: 26121231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
    You R; Mori T; Ke L; Wan Y; Zhang Y; Luo F; Feng D; Yu G; Liu J
    Menopause; 2021 Dec; 29(2):210-218. PubMed ID: 34930866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
    Dempster DW; Zhou H; Recker RR; Brown JP; Recknor CP; Lewiecki EM; Miller PD; Rao SD; Kendler DL; Lindsay R; Krege JH; Alam J; Taylor KA; Janos B; Ruff VA
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1353-63. PubMed ID: 26859106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
    Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
    Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
    J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.